(Q80703198)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

[Complement activation products (C3a and C5b-9) as markers of activity of dermatomyositis. Comparison with usual biochemical parameters] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

A Campo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

G Hausmann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

R M Martí

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

T Estrach

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

J M Grau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

J M Porcel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

C Herrero

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

Actas Dermo-Sifiliográficas

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

403-414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Polymyositis, dermatomyositis and inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Polymyositis: its presentation, morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Myoglobinemia and myoglobinuria in patients with myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Radioimmunoassay of serum myoglobin in polymyositis and other conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Serum myoglobin and creatine kinase concentrations in patients with polymyositis or dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

[Serum hepatocyte growth factor (HGF) in patients with inflammatory myopathies]

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Fat-suppressed MR imaging of myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Antimyosin scintigraphy compared with magnetic resonance imaging in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Muscle tissue oxygenation as a functional tool in the follow up of dermatomyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Decreased aerobic capacity in children with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Clinical significance of von Willebrand factor in patients with adult dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Activation of complement and coagulation in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Dermatomyositis in 132 Patients with Different Clinical Subtypes: Cutaneous Signs, Constitutional Symptoms and Circulating Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Dermatomyositis with elevated serum hyaluronate

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Serum concentrations of carboxyterminal propeptide of type 1 procollogen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Elevated serum levels of manganese superoxide dismutase in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Detection of the levels of neuropeptides, ACTH and cortisol in the blood of patients with polymyositis/dermatomyositis and their significance

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Vascular Deposits of Immunoglobulin and Complement in Idiopathic Inflammatory Myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Dermatomyositis (systemic angiopathy) of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

The childhood type of dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Microvascular changes in skeletal muscle in idiopathic inflammatory myopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Microvascular deposition of complement membrane attack complex in dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Microvascular changes in early and advanced dermatomyositis: a quantitative study

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis?

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Immune mechanisms in myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

Complement activation in patients with systemic lupus erythematosus without nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

The value of complement activation products in the assessment of systemic lupus erythematosus flares

1 reference

https://api.crossref.org/works/10.1016%2FS1578-2190%2807%2970473-0

7 January 2021

10.1016/S1578-2190(07)70473-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17663930%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference